bioMérieux S.A. (BMXMF) Research

Operating on a global scale, bioMérieux S.A. designs and produces in vitro diagnostic solutions specifically for detecting infectious diseases across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The firm's offerings encompass diagnostic systems that analyze biological samples to identify infectious diseases, cardiovascular conditions, and various types of cancer. Furthermore, it provides essential microbiological testing for quality assurance within the food, pharmaceutical, cosmetics, and veterinary industries. Its diverse clientele includes clinical and hospital laboratories, medical professionals, blood banks, and industrial control facilities. Founded in 1963, initially under the name B-D Mérieux, bioMérieux S.A. is headquartered in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.

Market snapshot

Symbol
BMXMF
Price
$78.00
Day change
0.00%
Market cap
$8.1B
P/E ratio
20.47x
52-week range
77-152
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 1 month

Peer companies

  • Agilent Technologies, Inc. (A)
  • Applied DNA Sciences, Inc. (APDN)
  • CareDx, Inc (CDNA)
  • Charles River Laboratories International, Inc. (CRL)
  • Danaher Corporation (DHR)
  • FONAR Corporation (FONR)
  • Guardant Health, Inc. (GH)
  • ICON Public Limited Company (ICLR)

Open bioMérieux S.A. (BMXMF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.